MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (BioSyent, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 16 and Wednesday, April 17, 2024. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent's business and corporate activities on Wednesday, April 17 at 3:30pm EDT.
Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference. These one-on-one meetings can be requested by registered attendees through the conference portal online: https://www.bloomburton.com/conference/.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units.
As of the date of this press release, the Company has 11,617,573 common shares outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.